SCHEMBL1768688

SCHEMBL1768688

NC1(OC=O)CCC(=O)CC1

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.34
CYP2C9 P11712 1/20 0.34
KMT2A Q03164 1/20 0.34
GAA P10253 1/20 0.30
RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL61083 0.80
Hydrochloric Acid SCHEMBL8681308 0.78
Hydrochloric Acid SCHEMBL5960763 0.75
SCHEMBL61974 0.75
SCHEMBL61735 0.75
SCHEMBL60474 0.73 TSHR (0.32)
Hydrochloric Acid SCHEMBL3168559 0.73
SCHEMBL61654 0.73 TSHR (0.32)
SCHEMBL62222 0.73 TSHR (0.32)
Hydrochloric Acid SCHEMBL29152267 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563135-B Alpha (V) beta (6) integrin binding peptides and methods of use thereof 加利福尼亚大学董事会 2024-01-23 CN disclosed
US-20230346960-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-11-02 US disclosed
US-11612663-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-28 US disclosed
US-11246961-B2 Engineered scaffolds for vascularized tissue repair THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-02-15 US disclosed
EP-3426700-B1 ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR UNIV CALIFORNIA (US) 2021-12-15 EP disclosed
CN-106573031-B Double-ended pegylated integrin-binding peptides and methods of use thereof 加利福尼亚大学董事会 2021-05-28 CN disclosed
CN-112672747-A Peptides for activating cell signalling in osteoprogenitor cells 加利福尼亚大学董事会 2021-04-16 CN disclosed
US-20210093728-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-04-01 US disclosed
EP-3280723-B1 BACKBONE-CYCLIZED PEPTIDOMIMETICS POLYPHOR AG (CH) 2021-01-06 EP disclosed
US-10730911-B2 Backbone-cyclized peptidomimetics with GLP-1R modulating activity UNIVERSITAT ZURICH (CH) 2020-08-04 US disclosed
US-20160017000-A1 RGD-CONTAINING CYCLIC PEPTIDES UNIV CALIFORNIA (US) 2016-01-21 US disclosed
US-9180395-B2 Porous thin films THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-11-10 US disclosed
US-8754038-B2 Template-fixed peptidomimetics with CCR10 antagonistic activity POLYPHOR AG (CH) 2014-06-17 US disclosed
US-20130129972-A1 Porous Thin Films THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-05-23 US disclosed
US-20120283168-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY POLYPHOR AG (CH) 2012-11-08 US disclosed
EP-2501715-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY Polyphor Ag (CH) 2012-09-26 EP disclosed
WO-2011079015-A1 RGD-CONTAINING CYCLIC PEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-06-30 WO disclosed
WO-2011060832-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY POLYPHOR AG (CH) 2011-05-26 WO disclosed
WO-2011060937-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY POLYPHOR AG (CH) 2011-05-26 WO disclosed
WO-2011060229-A1 POROUS THIN FILMS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10730911-B2 Backbone-cyclized peptidomimetics with GLP-1R modulating activity GLP1R, GIPR, SSTR1 MEN1 645/4885CYP2C9 2864/4885KMT2A 3930/4885
US-20230346960-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, PDGFRB, TEK MEN1 4811/4885CYP2C9 4598/4885KMT2A 4334/4885
US-20120283168-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY CCR10, CCR1, CCRL2 MEN1 3852/4885CYP2C9 3612/4885KMT2A 3431/4885
US-20210093728-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, PDGFRB, TEK MEN1 4811/4885CYP2C9 4598/4885KMT2A 4334/4885
US-11246961-B2 Engineered scaffolds for vascularized tissue repair FLT4, FLT1, KDR MEN1 2992/4885CYP2C9 4415/4885KMT2A 4128/4885
US-11612663-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair PDGFA, PDGFRB, TEK MEN1 4811/4885CYP2C9 4598/4885KMT2A 4334/4885
US-20160017000-A1 RGD-CONTAINING CYCLIC PEPTIDES ITGAV, ITGB3, ITGAL MEN1 3074/4885CYP2C9 4552/4885KMT2A 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.